1. A Deep Dive Into CVOTs

3. Complications of Diabetes

4. SAVOR, EXAMINE, and TECOS Key Results

5. EMPA-REG OUTCOME Cardiovascular Outcomes and Death From Any Cause

6. EMPA-REG OUTCOME HbA1c Levels and Blood Pressure

7. EMPA-REG OUTCOME Renal Outcomes

8. ELIXA Lixisenatide CVOT

9. LEADER Liraglutide CVOT

10. Lixisenatide and Liraglutide

11. Empagliflozin and Liraglutide

12. Individual Components of the Primary Endpoint

13. Drug Safety GLP-1 Receptor Agonists and SGLT2 Inhibitors

14. SGLT2 Inhibitors and GLP-1 Receptor Agonists: FDA Warnings and Precautions

15. Clinical Application of These CVOT Data

16. Are There Patient Populations That Favor Use of One Class Over Another?

17. FIGHT Study

18. Ongoing SGLT2 and DPP-4 Inhibitor CVOTs

19. Ongoing GLP-1 Receptor Agonist CVOTs

20. Closing Comments

21. Abbreviations